NRX Pharmaceuticals, Inc. Cost of Revenue
NRX Pharmaceuticals, Inc. (NRXP) reported Cost of Revenue of $675.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. cost of revenue for the quarter ending 2026-06-30 was $675.00K.
- NRX Pharmaceuticals, Inc. cost of revenue for the quarter ending 2026-03-31 was $631.00K.
- NRX Pharmaceuticals, Inc. cost of revenue for the quarter ending 2025-12-31 was $408.00K.
- NRX Pharmaceuticals, Inc. cost of revenue for the quarter ending 2025-09-30 was $97.00K.
- NRX Pharmaceuticals, Inc. cost of revenue for fiscal 2025 was $505.00K.
- NRX Pharmaceuticals, Inc. cost of revenue for fiscal 2024 was $0.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $675.00K 10-Q · filed 2026-08-14 | $1.31M 10-Q · filed 2026-08-14 | $1.71M derived: sum of 3 quarters · filed 2026-08-14 | $1.81M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $631.00K 10-Q · filed 2026-05-15 | $1.04M derived: sum of 2 quarters · filed 2026-05-15 | $1.14M derived: sum of 3 quarters · filed 2026-05-15 | $1.14M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $505.00K derived: sum of 2 quarters · filed 2026-03-23 | $505.00K derived: sum of 3 quarters · filed 2026-08-14 | $505.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $97.00K 10-Q · filed 2025-11-14 | $97.00K derived: sum of 2 quarters · filed 2026-08-14 | $97.00K 10-Q · filed 2025-11-14 | $97.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $0.00 derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |